3] Nonstandard abbreviations: TF, tissue factor; FVIIa, activated factor VII; TM, thrombomodulin; PC, protein C; EPCR, endothelial protein C receptor; APC, activated PC; PS, protein S; AT, antithrombin; TFPI, tissue factor pathway inhibitor; tPA, tissue plasminogen activator
; uPA, urokinase plasminogen activator
; PAI, plasminogen activator
inhibitor; PI, plasmin inhibitor; TAFI, thrombin activatable fibrinolysis inhibitor; ROTEM/TEG, thromboelastometry/thromboelastography; T2MR, T2 magnetic resonance.
Recombinant tissue plasminogen activator
(rtPA), which is commonly used for the treatment of myocardial infarction and stroke in adults, has also been used to treat cardiac thrombi in patients with congenital heart disease and right-to-left shunting (2), (3), (4).
inhibitor type-1 (part two): role for failure of thrombolytic therapy.
The thrombolytic agent tissue plasminogen activator
(tPA) is the only therapeutic agent approved by the US Food and Drug Administration for the treatment of patients with acute ischemic stroke.
Recombinant tissue-type plasminogen activator
(alteplase) for ischemic stroke 3 to 5 hours after symptom onset.
AnaSpec is pleased to introduce two plasminogen activator
assay kits - the SensoLyteO AFC Urokinase (uPA) Assay Kit and the SensoLyteO AMC tPA Assay Kit.
The serine protease, urokinase-type plasminogen activator
(uPA) plays an important role in tissue remodeling, cell migration and wound healing (Toriseva and Kahari, 2008; Watanabe et al.
Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide and urokinase-type plasminogen activator
in breast cancer patients.
The team obtained MR scans immediately before and approximately four hours after administration of intravenous tissue plasminogen activator
, or tPA, a drug that dissolves blood clots.
PAION AG, Aachen, Germany, a company focusing on the development of treatment opportunities for stroke and other thrombotic diseases has initiated a new plasminogen activator
program, which is intended to serve as a long-term life cycle management tool for Desmoteplase and a mid term option for indications not within the current profile and development program of Desmoteplase.
OAHU, HAWAII -- Inadvertent over-dosing of ischemic stroke patients with tissue plasminogen activator
can significantly undermine the drug's effectiveness, Buddy Connors, M.
The two agents, which were launched in Japan in May 1991, are based on a recombinant tissue plasminogen activator
developed by US firm Genentech.